A Novel Blockade CD47 Antibody With Therapeutic Potential for Cancer.
A Novel Blockade CD47 Antibody With Therapeutic Potential for Cancer.
复制标题
一种具有癌症治疗潜力的新型阻断 CD47 抗体
DOI：
10.3389/fonc.2020.615534
复制
发表时间：
2020
影响因子：
4.7
通讯作者：
Xiong D
中科院分区：
文献类型：
--
作者：
Lin F;Xiong M;Hao W;Song Y;Liu R;Yang Y;Yuan X;Fan D;Zhang Y;Hao M;Ye Z;Lu Y;Zhang Y;Wang J;Xiong D
巨噬细胞作为天然免疫系统的组成部分，在抗肿瘤反应中起着至关重要的作用。针对CD47的策略正在成为癌症治疗的热点。巨噬细胞通过表达CD47来区分“自我”和“非自我”。抗CD47抗体阻断巨噬细胞信号调节蛋白α(Sirpα)与肿瘤表面CD47的相互作用。在这项研究中，我们报道并评价了一种新的抗CD47封闭抗体2C8，它具有高亲和力和巨大的抗癌作用。更具体地说，2C8在体外显著诱导巨噬细胞，包括促肿瘤亚型M2巨噬细胞杀伤肿瘤细胞，并被证明比商用抗CD47单抗B6H12.2更有效。在体内，2C8控制肿瘤生长并延长异种移植小鼠的生存时间。2C8的抗肿瘤作用可能适用于许多其他癌症。新的CD47抗体的产生有助于巩固针对巨噬细胞治疗恶性肿瘤的临床兴趣，此外，当患者对其他检查点治疗耐药或难治或在此类治疗后复发时，CD47抗体可作为补充治疗。
Macrophages as components of the innate immune system play a critical role in antitumor responses. Strategies for targeting CD47 are becoming a hot spot for cancer therapy. The expression of CD47 is exercised by macrophages to make a distinction between “self” or “nonself.” Anti-CD47 antibodies block the interaction between macrophage signal regulatory protein-α (SIRPα) and tumor surface CD47. In this study, we report and assess a novel anti-CD47 blocking antibody named 2C8, which exhibits high affinity and tremendous anticancer effects. More concretely, 2C8 significantly induces macrophages, including protumorigenic subtype M2 macrophages killing tumor cells in vitro, and is revealed to be more effective than commercially available anti-CD47 mAb B6H12.2. In vivo, 2C8 controls tumor growth and extends survival of xenograft mice. The antitumor ability of 2C8 might be applicable to many other cancers. The generation of a novel CD47 antibody contributes to consolidating clinical interest in targeting macrophages for the treatment of malignancy and, moreover, as a supplement therapy when patients are resistant or refractory to other checkpoint therapies or relapse after such treatments.
登录
查看更多内容
CD47通过抑制巨噬细胞吞噬作用促进卵巢癌进展
影响因子：
--
作者：
Liu R;Wei H;Gao P;Yu H;Wang K;Fu Z;Ju B;Zhao M;Dong S;Li Z;He Y;Huang Y;Yao Z
通讯作者：
Yao Z
影响因子：
11.2
作者：
Chao MP;Alizadeh AA;Tang C;Jan M;Weissman-Tsukamoto R;Zhao F;Park CY;Weissman IL;Majeti R
通讯作者：
Majeti R
CD47是人类急性髓样白血病干细胞的不良预后因素和治疗抗体靶标。
影响因子：
64.5
作者：
Majeti R;Chao MP;Alizadeh AA;Pang WW;Jaiswal S;Gibbs KD Jr;van Rooijen N;Weissman IL
通讯作者：
Weissman IL
DOI：
10.1038/nrclinonc.2016.217
发表时间：
2017-07
期刊：
Nature reviews. Clinical oncology
影响因子：
--
作者：
Mantovani A;Marchesi F;Malesci A;Laghi L;Allavena P
通讯作者：
Allavena P
影响因子：
15.9
作者：
Gul, Nuray;Babes, Liane;van Egmond, Marjolein
通讯作者：
van Egmond, Marjolein